Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Genetic therapy may help children with Angelman syndrome to overcome seizures

Genetic therapy may help children with Angelman syndrome to overcome seizures

Angelman syndrome is a genetic disease with no cure. Children grow up with severe intellectual disabilities and a range of other problems, arguably the worst of which are epileptic seizures. Now scientists at the UNC School of Medicine have found evidence that genetic therapy may prevent the enhanced seizure susceptibility.

Published in the Journal of Clinical Investigation, the research marks the first time scientists were able to reduce seizure susceptibility in mice by activating a dormant copy of the UBE3A gene so it could replace the faulty mutant version. While replacing the faulty gene in juveniles reduced seizures, replacing the faulty gene in adult mice had no effect.

The UNC scientists also found evidence that the loss of this gene in Angelman syndrome promotes seizures by impairing the normal activity of inhibitory neurons – cells that normally keep brain circuits from being overstimulated.

“These findings should be very useful in the development and testing of therapies for Angelman syndrome,” said senior author Benjamin D. Philpot, PhD, Kenan Distinguished Professor in the Department of Cell Biology and Physiology, associate director of the UNC Neuroscience Center, and member of the UNC Autism Research Center.

Angelman syndrome, named for the pediatrician who first described it in 1965, afflicts roughly one in 20,000 people, which implies that there are more than 16,000 people with the syndrome in the United States alone. The syndrome is caused by the loss of function of a single gene, UBE3A, but with an odd twist: the mutant or deleted copy of UBE3A is the one inherited from the patient’s mother. This maternal copy is crucial in neurons because – for reasons still unknown – the paternal copy of UBE3A is silenced in these cells via a mechanism called genomic imprinting.

UBE3A encodes a protein that works in an important cellular waste-disposal and gene-regulating system. Precisely how the absence of this protein in neurons causes Angelman syndrome has never been clear. Even so, scientists have been working on candidate therapies to restore UBE3A activity in neurons, thereby preventing or reversing some or all of the features of the disease. Among these features is epilepsy, which afflicts about 90 percent of Angelman syndrome patients, who typically do not respond well to standard anti-seizure medications.

Some aspects of the disease reflect abnormal prenatal and early postnatal development, and may never be reversible with treatments that start years after birth. But epilepsy often doesn’t start in Angelman patients until age 2 or 3, suggesting that early life replacement of UBE3A might cure it or prevent it. Philpot and colleagues decided to investigate how early the gene reinstatement needed to take place. They took advantage of an Angelman syndrome mouse model, in which researchers inserted a working copy of the UBE3A gene that would lie dormant in brain cells until scientists turned it on with a chemical switch.

The scientists found that switching on UBE3A failed to prevent or reverse the high susceptibility to seizures in adult Angelman mice. However, switching on the gene when the mice were just three weeks old made them as resistant to seizures as ordinary mice.

“Three weeks of age for a mouse corresponds to early childhood for a human, so this suggests that there may be a window of opportunity in childhood for the prevention of Angelman syndrome epilepsy,” said first author Bin Gu, PhD, a postdoctoral researcher in the Philpot Lab who performed most of the key experiments.

Another big question for Angelman syndrome researchers has to do with the neurons affected by the disease. Philpot wondered, to treat the condition successfully, would UBE3A activity need to be restored in all types of neurons or just in some?

Philpot’s team removed functional UBE3A from excitatory neurons – which trigger activity in connected neurons – and observed that the resulting mice were unaffected. Then they blocked the gene just in inhibitory neurons, whose activity normally quiets and regulates connected neurons, thereby preventing the neural hyperactivity that can trigger seizures. With UBE3A gone from the inhibitory neurons, the mice became even more susceptible to seizures than if UBE3A were absent from all neurons.

“This result implies that if you want to limit epilepsy in Angelman syndrome, you’ll need at least to restore the function of UBE3A in inhibitory neurons,” Philpot said.

The researchers gained another clue to the mechanism of Angelman syndrome seizures when they examined the brains of the seizure-prone mice, particularly in an area of the brain known as the hippocampus. They detected an abnormal accumulation of perineuronal nets (PNNs) – structures that surround neurons and block them from making new connections. Abnormal PNN formation has previously been linked to seizures. The scientists found that the abnormal PNN deposition did not occur in the young mice where UBE3A activity had been restored.

“We can now think of these abnormal PNNs as biomarkers for enhanced seizure susceptibility,” Philpot said. “We now want to determine if these structures actually cause seizure susceptibility, for example by disrupting the connections that inhibitory neurons normally would make in this brain region.”

Philpot and collaborators at UNC, along with other researchers elsewhere, are working on potential Angelman syndrome treatments, including drugs that would activate the previously silenced paternal copy of UBE3A in brain cells.

Source:

http://news.unchealthcare.org/news/2018/november/can-genetic-therapy-help-kids-with-angelman-syndrome-overcome-seizures

Tagged with:

About author

Related Articles